GU Cancers Symposium 2020

Complete Coverage

Combination Therapy for Advanced Urothelial Carcinoma Shows Promise in Early Clinical Trial

A combination of pembrolizumab and an antibody-drug conjugate demonstrated a 73% overall response rate in a phase 1/2 clinical trial.

Preoperative Bone Metastases Not Prognostic in mRCC

Bone metastases less predictive in the setting of cytoreductive nephrectomy.

Immune Checkpoint Inhibitors for mRCC Safe, Effective in a Real World Setting

In a single-center study of 177 patients with metastatic renal cell carcinoma who received at least a single dose of an immune checkpoint inhibitor, the median time to next treatment was 8.9 months and median overall survival time was 26.7 months.

CN for mRCC Does Not Up Survival in the Immune Checkpoint Inhibitor Era

In a study, cytoreductive nephrectomy was not independently associated with improved survival in patients with metastatic renal cell carcinoma receiving immune checkpoint inhibitors.

Neoadjuvant Immune-Chemotherapy Has Positive Effect in MIBC Cases

Combination neoadjuvant therapy with nivolumab and gemcitabine-cisplatin in patients with muscle-invasive bladder cancer resulted in significant pathologic downstaging at radical cystectomy, with manageable toxicities.

Metastasectomy Found to Prolong Survival in Selected mRCC Cases

In a study, metastasectomy was associated with significantly longer median progression-free and overall survival in some mRCC patients.

Ipilimumab Plus Nivolumab Effective for mRCC With Brain Metastases

Dual immunotherapy appears to have clinical efficacy beyond the first-line setting in patients with metastatic renal cell carcinoma with brain metastases.

Overall Survival in mCRPC Cases Linked to Number of Radium-223 Doses

Men with metastatic castration-resistant prostate cancer with predominantly bone metastases who receive more than 4 dose of radium-223 have significantly improved overall survival than those who receive 4 or fewer doses, a study found.

Novel Bladder Cancer Salvage Therapy Appears Safe, Effective

Nadofaragene firadenovec, a novel gene-mediated therapy, achieved a 53.4% complete response rate in patients with high-grade carcinoma in situ unresponsive to bacillus Calmette-Guérin, phase 3 trial results show.

Nivolumab Outperforms Everolimus in Advanced RCC, Study Confirms

In a long-term follow-up of the CheckMate trial, investigators observed consistently prolonged survival with nivolumab compared with everolimus.

Intermediate-Risk mRCC Patients Have Heterogeneous Survival Outcomes

Survival of patients with intermediate-risk metastatic renal cell carcinoma varied according to the number of IMDC or MSKCC risk factors.

Radium-223 Plus Sipuleucel-T Found to Slow mCRPC Progression

Combining sipuleucel-T and radium-223 improves progression-free survival among men with metastatic castration-resistant prostate cancer (mCRPC) who have bone predominant metastases, a randomized phase 2 study found.

Intermittent Enzalutamide Dosing for mCRPC Probed

In a small study, intermittent vs continuous dosing was associated with improved overall survival and prolonged time on treatment.

Prostate Cancer Death Risk Not Linked to 5-ARIs

Investigators found that men treated with 5-alpha-reductase inhibitors are not more likely to die from prostate cancer or any other cause.

Modest Survival Gains Reported in Newly Diagnosed Metastatic PCa

Despite the introduction in recent year of promising novel agents, men with newly diagnosed metastatic prostate cancer have experienced only a slight decline in death risk.

Cabazitaxel Linked to Better Pain Reduction in mCRPC

A new analysis of men in the CARD study showed that cabazitaxel improved pain response and decreased the likelihood of pain progression compared with either abiraterone or enzalutamide.

Longer Survival Seen With Sipuleucel-T Use in mCRPC

In a study of men with metastatic castration-resistant prostate cancer, sipuleucel-T immunotherapy used at any point during treatment was associated with a decreased risk of death compared with utilization of newer oral androgen pathway inhibitors therapy without sipuleucel-T.